• About us
• Contact

Advertisement

Organisation › Details

Ipsen S.A. (Euronext: IPN; ADR: IPSEY)

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). *

 

	Start	2007-08-25 existent
	Group	Ipsen (Group)
	Industry	pharmaceutical
	Person	Loew, David (Ipsen 202206 CEO before Sanofi 201606– EVP + General Manager Sanofi Pasteur)
	Person 2	le Chatelier, Aymeric (Ipsen 201603 CFO)
	Region	Paris
	Country	France
	Street	42 rue du Docteur Blanche
	City	75016 Paris
	Tel	+33-1-443043-43
		Address record changed: 2020-12-02
Basic data	Employees	F: 1,001 to 5,000 (2022-06-27)
	Currency	EUR
	Annual sales	1,671,100,000 (revenue, consolidated (2016) 2016-12-31)
	Profit	226,600,000 (2016-12-31)
	Cash	425,500,000 (2016-12-31)
		* Document for »About Section«: Ipsen S.A.. (6/27/22). "Press Release: Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology". Paris & Cambridge, MA.
		Record changed: 2024-07-14

Advertisement

More documents for Ipsen (Group)

• [1] Ipsen S.A.. (7/11/24). "Press Release: Ipsen and Foreseen Biotechnology Announce Exclusive Global Licensing Agreement for Antibody-Drug Conjugate with First-in-Class Potential". Paris....
• [2] Ipsen S.A.. (6/10/24). "Press Release: Ipsen’s Iqirvo Receives U.S. FDA Accelerated Approval as a First-in-Class PPAR Treatment for Primary Biliary Cholangitis". Paris....
• [3] Ipsen S.A.. (4/2/24). "Press Release: Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting solid tumors". Paris & San Francisco, CA....
• [4] Ipsen S.A.. (1/9/23). "Press Release: Ipsen to Acquire Albireo Accelerating Growth in Rare Disease with Treatments for Several Pediatric Liver Diseases". Paris & Boston, MA....
• [5] Ipsen S.A.. (6/27/22). "Press Release: Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology". Paris & Cambridge, MA....
• [6] Genfit S.A.. (12/17/21). "Press Release: Ipsen and Genfit Enter into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-term Global Partnership". Paris....
• [7] Santhera Pharmaceuticals Holding AG. (11/4/21). "Press Release: Santhera Appoints Stephanie Brown as President North America and Member of the Executive Management Team". Pratteln....
• [8] Synthace Ltd.. (8/2/21). "Press Release: Synthace Unveils First Life Sciences R&D Cloud Addressing Complexity, Speed & Reproducibility for Scientists". London....
• [9] Ipsen S.A.. (9/25/20). "Press Release: Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer". Paris....
• [10] Ipsen S.A.. (1/24/20). "Press Release: Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria". Paris....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.